BioCentury | Feb 1, 2016
Company News

Cancer Therapeutics CRC, Wellcome Trust, Merck, Cancer Research UK deal

...and commercialize inhibitors of protein arginine methyltransferase 5 (PRMT5) . The inhibitors were developed by Cancer Therapeutics CRC...
...provide further details or financial terms, and Merck and CTx did not respond to inquiries. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Jan 28, 2016
Company News

Merck, CRT in deal for PRMT5 inhibitors

...treat cancer and non-cancer blood disorders. The inhibitors were developed by Australian cooperative research center Cancer Therapeutics CRC...
BioCentury | Mar 10, 2014
Company News

Alchemia, Cancer Research Technology deal

...declined to disclose details, and Alchemia could not be reached. The FAK inhibitors originate from Cancer Therapeutics CRC...
BioCentury | Mar 3, 2014
Company News

Cancer Therapeutics CRC (CTx) Pty. Ltd. cancer news

...developing compounds targeting metastatic melanoma. CTx declined to disclose details (see BioCentury, Sept 3, 2007). Cancer Therapeutics CRC...
BioCentury | Jun 10, 2013
Clinical News

Bionomics, Cancer Therapeutics CRC preclinical data

...CRC) Programme to discover, develop and commercialize cancer compounds. Bionomics Ltd. (ASX:BNO; OTCBB:BMICY), Thebarton, Australia Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Aug 20, 2012
Company News

Cancer Therapeutics CRC, Cancer Research U.K. deal

...are not disclosed, but added that the companies will share revenues from commercializing the products. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Jul 16, 2012
Clinical News

Cancer Therapeutics CRC preclinical data

...Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), markets Avastin in the U.S., while Roche markets it elsewhere. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Apr 9, 2012
Clinical News

Cancer Therapeutics CRC preclinical data

...Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), markets Avastin in the U.S., while Roche markets it elsewhere. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Oct 12, 2009
Company News

Cancer Therapeutics CRC, Duke University deal

...preclinical development and seek a partner for further development. The university is eligible for royalties. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Jun 22, 2009
Company News

Cancer Therapeutics CRC, Novation deal

Cancer Therapeutics CRC Pty. Ltd. , Bundoora, Australia Novation Pharmaceuticals Inc. , Vancouver, B.C. Business: Cancer The partners will combine Novation's Quest drug discovery technology and Cancer Therapeutics' small molecule compound library to identify small molecules against...
Items per page:
1 - 10 of 12
BioCentury | Feb 1, 2016
Company News

Cancer Therapeutics CRC, Wellcome Trust, Merck, Cancer Research UK deal

...and commercialize inhibitors of protein arginine methyltransferase 5 (PRMT5) . The inhibitors were developed by Cancer Therapeutics CRC...
...provide further details or financial terms, and Merck and CTx did not respond to inquiries. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Jan 28, 2016
Company News

Merck, CRT in deal for PRMT5 inhibitors

...treat cancer and non-cancer blood disorders. The inhibitors were developed by Australian cooperative research center Cancer Therapeutics CRC...
BioCentury | Mar 10, 2014
Company News

Alchemia, Cancer Research Technology deal

...declined to disclose details, and Alchemia could not be reached. The FAK inhibitors originate from Cancer Therapeutics CRC...
BioCentury | Mar 3, 2014
Company News

Cancer Therapeutics CRC (CTx) Pty. Ltd. cancer news

...developing compounds targeting metastatic melanoma. CTx declined to disclose details (see BioCentury, Sept 3, 2007). Cancer Therapeutics CRC...
BioCentury | Jun 10, 2013
Clinical News

Bionomics, Cancer Therapeutics CRC preclinical data

...CRC) Programme to discover, develop and commercialize cancer compounds. Bionomics Ltd. (ASX:BNO; OTCBB:BMICY), Thebarton, Australia Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Aug 20, 2012
Company News

Cancer Therapeutics CRC, Cancer Research U.K. deal

...are not disclosed, but added that the companies will share revenues from commercializing the products. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Jul 16, 2012
Clinical News

Cancer Therapeutics CRC preclinical data

...Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), markets Avastin in the U.S., while Roche markets it elsewhere. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Apr 9, 2012
Clinical News

Cancer Therapeutics CRC preclinical data

...Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), markets Avastin in the U.S., while Roche markets it elsewhere. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Oct 12, 2009
Company News

Cancer Therapeutics CRC, Duke University deal

...preclinical development and seek a partner for further development. The university is eligible for royalties. Cancer Therapeutics CRC Pty. Ltd....
BioCentury | Jun 22, 2009
Company News

Cancer Therapeutics CRC, Novation deal

Cancer Therapeutics CRC Pty. Ltd. , Bundoora, Australia Novation Pharmaceuticals Inc. , Vancouver, B.C. Business: Cancer The partners will combine Novation's Quest drug discovery technology and Cancer Therapeutics' small molecule compound library to identify small molecules against...
Items per page:
1 - 10 of 12